RATIONALE-315 Data Support Perioperative Tislelizumab Plus Neoadjuvant Chemo in Resectable NSCLC
Neoadjuvant tislelizumab plus platinum-based doublet chemotherapy followed by surgery and adjuvant tislelizumab demonstrated efficacy in resectable non–small cell lung cancer.
Source: onclive.com